These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 22991264

  • 21. Differential Notch1 and Notch2 expression and frequent activation of Notch signaling in gastric cancers.
    Sun Y, Gao X, Liu J, Kong QY, Wang XW, Chen XY, Wang Q, Cheng YF, Qu XX, Li H.
    Arch Pathol Lab Med; 2011 Apr; 135(4):451-8. PubMed ID: 21466361
    [Abstract] [Full Text] [Related]

  • 22. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 23. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
    Yan P, Su Z, Zhang Z, Gao T.
    Int J Oncol; 2019 Nov 01; 55(5):988-1002. PubMed ID: 31485599
    [Abstract] [Full Text] [Related]

  • 24. Hes1, an important gene for activation of hepatic stellate cells, is regulated by Notch1 and TGF-β/BMP signaling.
    Zhang K, Zhang YQ, Ai WB, Hu QT, Zhang QJ, Wan LY, Wang XL, Liu CB, Wu JF.
    World J Gastroenterol; 2015 Jan 21; 21(3):878-87. PubMed ID: 25624721
    [Abstract] [Full Text] [Related]

  • 25. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer.
    Jin Z, Cheng X, Feng H, Kuang J, Yang W, Peng C, Shen B, Qiu W.
    Cell Physiol Biochem; 2017 Jan 21; 44(4):1471-1484. PubMed ID: 29190616
    [Abstract] [Full Text] [Related]

  • 26. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway.
    Hu Y, Wen Q, Cai Y, Liu Y, Ma W, Li Q, Song F, Guo Y, Zhu L, Ge J, Zeng Q, Wang J, Yin C, Zheng G, Ge M.
    Phytomedicine; 2023 Jan 21; 108():154528. PubMed ID: 36343549
    [Abstract] [Full Text] [Related]

  • 27. Membrane receptor-dependent Notch1/Hes1 activation by melatonin protects against myocardial ischemia-reperfusion injury: in vivo and in vitro studies.
    Yu L, Liang H, Lu Z, Zhao G, Zhai M, Yang Y, Yang J, Yi D, Chen W, Wang X, Duan W, Jin Z, Yu S.
    J Pineal Res; 2015 Nov 21; 59(4):420-33. PubMed ID: 26308963
    [Abstract] [Full Text] [Related]

  • 28. Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.
    Somnay YR, Dull BZ, Eide J, Jaskula-Sztul R, Chen H.
    Cancer Gene Ther; 2015 Oct 21; 22(10):496-505. PubMed ID: 26403073
    [Abstract] [Full Text] [Related]

  • 29. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells.
    Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan YL, Du R, Zheng GR, Xiong YM, Xu HL, Fan DM.
    Exp Cell Res; 2010 Jan 15; 316(2):149-57. PubMed ID: 19800882
    [Abstract] [Full Text] [Related]

  • 30. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer.
    Piazzi G, Fini L, Selgrad M, Garcia M, Daoud Y, Wex T, Malfertheiner P, Gasbarrini A, Romano M, Meyer RL, Genta RM, Fox JG, Boland CR, Bazzoli F, Ricciardiello L.
    Oncotarget; 2011 Dec 15; 2(12):1291-301. PubMed ID: 22249198
    [Abstract] [Full Text] [Related]

  • 31. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L, Qin Y, Out-Luiting JJ, Vermeer KG, Whittaker S, van Es JH, Tensen CP, Vermeer MH.
    J Invest Dermatol; 2012 Dec 15; 132(12):2810-7. PubMed ID: 22718117
    [Abstract] [Full Text] [Related]

  • 32. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
    Fang KM, Lin TC, Chan TC, Ma SZ, Tzou BC, Chang WR, Liu JJ, Chiou SH, Yang CS, Tzeng SF.
    Glia; 2013 Sep 15; 61(9):1402-17. PubMed ID: 23832679
    [Abstract] [Full Text] [Related]

  • 33. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X, Park S, Lee WK, Cheng SY.
    Endocr Relat Cancer; 2019 Sep 15; 26(9):739-750. PubMed ID: 31272080
    [Abstract] [Full Text] [Related]

  • 34. Prognostic significance of Hes-1, a downstream target of notch signaling in hepatocellular carcinoma.
    Zou JH, Xue TC, Sun C, Li Y, Liu BB, Sun RX, Chen J, Ren ZG, Ye SL.
    Asian Pac J Cancer Prev; 2015 Sep 15; 16(9):3811-6. PubMed ID: 25987042
    [Abstract] [Full Text] [Related]

  • 35. Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells.
    Kunnimalaiyaan M, Yan S, Wong F, Zhang YW, Chen H.
    Surgery; 2005 Dec 15; 138(6):1137-42; discussion 1142. PubMed ID: 16360401
    [Abstract] [Full Text] [Related]

  • 36. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
    Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2004 Dec 15; 10(24):8594-602. PubMed ID: 15623643
    [Abstract] [Full Text] [Related]

  • 37. Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.
    Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR, Kunnimalaiyaan M, Chen H.
    Ann Surg; 2008 Jun 15; 247(6):1036-40. PubMed ID: 18520232
    [Abstract] [Full Text] [Related]

  • 38. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K, Sato F, Tamagawa S, Gunduz M, Onoda N, Uchino S, Muragaki Y, Hotomi M.
    Sci Rep; 2019 Oct 10; 9(1):14616. PubMed ID: 31601917
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression.
    Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J, Zweidler-McKay PA.
    Blood; 2011 Mar 10; 117(10):2891-900. PubMed ID: 21224467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.